# Nkarta, Inc.: financial statements, quarterly

NKTX · Nasdaq · CIK 1787400 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nktx.md) · [Financials](/companies/nktx/financials.md) · [Filings](/companies/nktx/filings.md) · [Insiders](/companies/nktx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nktx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [22.2](/filings/0000950170-24-123395.md) | [23.3 d](/filings/0000950170-25-045262.md) | [25.2](/filings/0000950170-25-071455.md) | [23.1](/filings/0001193125-25-178964.md) | [25.3](/filings/0001193125-25-274304.md) | [23.1 d](/filings/0001787400-26-000006.md) | [24.2](/filings/0001787400-26-000013.md) | [20.8](/filings/0001787400-26-000017.md) | [20.2](/filings/0001193125-25-274304.md) | [25.3 d](/filings/0001787400-26-000006.md) | [25.0](/filings/0001787400-26-000013.md) | [29.0](/filings/0001787400-26-000017.md) |
| Operating income | $m | [(29.3)](/filings/0000950170-24-123395.md) | [(31.2) d](/filings/0000950170-25-045262.md) | [(32.8)](/filings/0000950170-25-071455.md) | [(30.7)](/filings/0001193125-25-178964.md) | [(33.8)](/filings/0001193125-25-274304.md) | [(30.9) d](/filings/0001787400-26-000006.md) | [(36.6)](/filings/0001787400-26-000013.md) | [(27.2)](/filings/0001787400-26-000017.md) | [(27.3)](/filings/0001193125-25-274304.md) | [(31.0) d](/filings/0001787400-26-000006.md) | [(30.9)](/filings/0001787400-26-000013.md) | [(43.1)](/filings/0001787400-26-000017.md) |
| Income tax | $m | [0.0](/filings/0000950170-23-062091.md) | [0.0 d](/filings/0000950170-25-045262.md) | [0.0](/filings/0000950170-25-071455.md) | [0.0](/filings/0001193125-25-178964.md) | [0.0](/filings/0001193125-25-274304.md) | [0.0 d](/filings/0001787400-26-000006.md) | [0.0](/filings/0001787400-26-000013.md) | [0.0](/filings/0001193125-25-178964.md) | [0.0](/filings/0001193125-25-274304.md) | [0.0 d](/filings/0001787400-26-000006.md) | [0.0](/filings/0001787400-26-000013.md) | [0.0 d](/filings/0001787400-26-000017.md) |
| Net income | $m | [(25.6)](/filings/0000950170-24-123395.md) | [(27.8) d](/filings/0000950170-25-045262.md) | [(29.5)](/filings/0001193125-25-274304.md) | [(25.0)](/filings/0001193125-25-274304.md) | [(28.3)](/filings/0001193125-25-274304.md) | [(25.9) d](/filings/0001787400-26-000006.md) | [(32.0)](/filings/0001787400-26-000017.md) | [(23.0)](/filings/0001787400-26-000017.md) | [(21.7)](/filings/0001193125-25-274304.md) | [(27.4) d](/filings/0001787400-26-000006.md) | [(27.8)](/filings/0001787400-26-000017.md) | [(40.4)](/filings/0001787400-26-000017.md) |
| Diluted EPS | $ per share | [(0.52)](/filings/0000950170-24-123395.md) | not reported | [(0.58)](/filings/0000950170-25-071455.md) | [(0.34)](/filings/0001193125-25-178964.md) | [(0.39)](/filings/0001193125-25-274304.md) | not reported | [(0.43)](/filings/0001787400-26-000013.md) | [(0.31)](/filings/0001787400-26-000017.md) | [(0.29)](/filings/0001193125-25-274304.md) | not reported | [(0.37)](/filings/0001787400-26-000013.md) | [(0.54)](/filings/0001787400-26-000017.md) |
| Basic EPS | $ per share | [(0.52)](/filings/0000950170-24-123395.md) | not reported | [(0.58)](/filings/0000950170-25-071455.md) | [(0.34)](/filings/0001193125-25-178964.md) | [(0.39)](/filings/0001193125-25-274304.md) | not reported | [(0.43)](/filings/0001787400-26-000013.md) | [(0.31)](/filings/0001787400-26-000017.md) | [(0.29)](/filings/0001193125-25-274304.md) | not reported | [(0.37)](/filings/0001787400-26-000013.md) | [(0.54)](/filings/0001787400-26-000017.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [38.3](/filings/0000950170-24-123395.md) | [31.0](/filings/0000950170-25-045262.md) | [250](/filings/0000950170-25-071455.md) | [120](/filings/0001193125-25-178964.md) | [57.0](/filings/0001193125-25-274304.md) | [27.9](/filings/0001787400-26-000006.md) | [52.6](/filings/0001787400-26-000013.md) | [53.4](/filings/0001787400-26-000017.md) | [60.1](/filings/0001193125-25-274304.md) | [39.6](/filings/0001787400-26-000017.md) | [27.4](/filings/0001787400-26-000013.md) | [25.0](/filings/0001787400-26-000017.md) |
| Current assets | $m | [281](/filings/0000950170-23-062091.md) | [253](/filings/0000950170-25-045262.md) | [443](/filings/0000950170-24-056980.md) | [332](/filings/0000950170-24-096186.md) | [290](/filings/0000950170-24-123395.md) | [273](/filings/0001787400-26-000006.md) | [272](/filings/0000950170-25-071455.md) | [297](/filings/0001193125-25-178964.md) | [289](/filings/0001193125-25-274304.md) | [283](/filings/0001787400-26-000017.md) | [236](/filings/0001787400-26-000013.md) | [188](/filings/0001787400-26-000017.md) |
| Total assets | $m | [406](/filings/0000950170-23-062091.md) | [379](/filings/0000950170-25-045262.md) | [577](/filings/0000950170-24-056980.md) | [554](/filings/0000950170-24-096186.md) | [532](/filings/0000950170-24-123395.md) | [501](/filings/0001787400-26-000006.md) | [471](/filings/0000950170-25-071455.md) | [448](/filings/0001193125-25-178964.md) | [427](/filings/0001193125-25-274304.md) | [404](/filings/0001787400-26-000017.md) | [372](/filings/0001787400-26-000013.md) | [338](/filings/0001787400-26-000017.md) |
| Current liabilities | $m | [25.6](/filings/0000950170-23-062091.md) | [23.3](/filings/0000950170-25-045262.md) | [22.2](/filings/0000950170-24-056980.md) | [20.9](/filings/0000950170-24-096186.md) | [22.5](/filings/0000950170-24-123395.md) | [18.9](/filings/0001787400-26-000006.md) | [18.8](/filings/0000950170-25-071455.md) | [18.9](/filings/0001193125-25-178964.md) | [19.0](/filings/0001193125-25-274304.md) | [22.3](/filings/0001787400-26-000017.md) | [18.2](/filings/0001787400-26-000013.md) | [23.6](/filings/0001787400-26-000017.md) |
| Total liabilities | $m | [109](/filings/0000950170-23-062091.md) | [106](/filings/0000950170-25-045262.md) | [103](/filings/0000950170-24-056980.md) | [101](/filings/0000950170-24-096186.md) | [101](/filings/0000950170-24-123395.md) | [93.2](/filings/0001787400-26-000006.md) | [91.8](/filings/0000950170-25-071455.md) | [90.6](/filings/0001193125-25-178964.md) | [89.3](/filings/0001193125-25-274304.md) | [91.9](/filings/0001787400-26-000017.md) | [86.2](/filings/0001787400-26-000013.md) | [89.9](/filings/0001787400-26-000017.md) |
| Shareholders' equity | $m | [297](/filings/0000950170-24-123395.md) | [273](/filings/0001787400-26-000006.md) | [474](/filings/0001193125-25-274304.md) | [453](/filings/0001193125-25-274304.md) | [431](/filings/0001193125-25-274304.md) | [408](/filings/0001787400-26-000017.md) | [379](/filings/0001787400-26-000017.md) | [358](/filings/0001787400-26-000017.md) | [338](/filings/0001193125-25-274304.md) | [312](/filings/0001787400-26-000017.md) | [286](/filings/0001787400-26-000017.md) | [248](/filings/0001787400-26-000017.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.3) d](/filings/0000950170-24-123395.md) | [(23.4) d](/filings/0000950170-25-045262.md) | [(28.5)](/filings/0000950170-25-071455.md) | [(21.9) d](/filings/0001193125-25-178964.md) | [(24.5) d](/filings/0001193125-25-274304.md) | [(24.8) d](/filings/0001787400-26-000006.md) | [(29.6)](/filings/0001787400-26-000013.md) | [(18.8) d](/filings/0001787400-26-000017.md) | [(18.7) d](/filings/0001193125-25-274304.md) | [(21.6) d](/filings/0001787400-26-000006.md) | [(28.2)](/filings/0001787400-26-000013.md) | [(24.2) d](/filings/0001787400-26-000017.md) |
| Capital expenditure | $m | [6.2 d](/filings/0000950170-24-123395.md) | [6.8 d](/filings/0000950170-25-045262.md) | [0.2](/filings/0000950170-25-071455.md) | [2.4 d](/filings/0001193125-25-178964.md) | [0.8 d](/filings/0001193125-25-274304.md) | [1.1 d](/filings/0001787400-26-000006.md) | [0.5](/filings/0001787400-26-000013.md) | [0.1 d](/filings/0001787400-26-000017.md) | [(0.0) d](/filings/0001193125-25-274304.md) | [0.6 d](/filings/0001787400-26-000006.md) | [0.4](/filings/0001787400-26-000013.md) | [0.2 d](/filings/0001787400-26-000017.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.6](/filings/0000950170-23-062091.md) | [48.9](/filings/0000950170-24-056980.md) | [49.0](/filings/0000950170-24-096186.md) | [49.1](/filings/0000950170-24-123395.md) | [50.7](/filings/0000950170-25-071455.md) | [73.5](/filings/0001193125-25-178964.md) | [73.6](/filings/0001193125-25-274304.md) | [73.9](/filings/0001787400-26-000013.md) | [74.0](/filings/0001787400-26-000017.md) | [74.0](/filings/0001193125-25-274304.md) | [74.3](/filings/0001787400-26-000013.md) | [74.5](/filings/0001787400-26-000017.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 71,624,791 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001787400-26-000017.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.